SEC Form 4 · accession 0001209191-16-093846
ACHILLION PHARMACEUTICALS INC · ACHN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert L Van Nostrand
Director
Period of report
Jan 25, 2016
Accepted (ET)
Jan 27, 2016 · 5:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070336
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.54 | Jan 25, 2016 | A | 30,000 | A | — | Jan 25, 2026 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1Such option grant vests as to 25% on the date of grant and as to an additional 2.08% at the end of each monthly period thereafter.